A prevention-focused Phase 3 trial
First participant expected in the first quarter of 2027.
CeD-LA-3002
CeD-LA-3002 is a prevention-focused Phase 3 trial designed to evaluate whether larazotide acetate can protect against gluten-induced intestinal injury and symptoms in adolescents and adults with well-controlled celiac disease. All participants enter the trial with biopsy-confirmed, well-controlled disease and receive a standardized gluten exposure under study supervision, at the upper range of estimated real-world inadvertent intake. The primary endpoint requires participants to maintain both the structure of the intestinal lining and control of symptoms. The trial is expected to enroll its first participant in the first quarter of 2027.
| Study design | Randomized, double-blind, placebo-controlled, multicenter trial with three parallel arms |
|---|---|
| Participants | Approximately 414 adolescents and adults, ages 12–80, with biopsy-confirmed, well-controlled celiac disease on a gluten-free diet for at least 12 months |
| Location | United States |
| Treatment period | 14 weeks of larazotide 0.25 mg, larazotide 0.5 mg, or placebo, taken three times daily before meals, including 12 weeks of standardized gluten exposure |
| First participant dosing | Anticipated in 1Q 2027 |
For patients
Information about eligibility and participating sites will be available through ClinicalTrials.gov and the study sites. To register your interest in the study, contact info@interludebio.com.
Patient FAQsFor clinicians and investigators
Clinicians and investigators interested in participating in or referring patients to CeD-LA-3002 can contact us at info@interludebio.com.
Clinical developmentLarazotide acetate is an investigational product that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any indication, and its safety and efficacy have not been established.